摘要
[目的]探讨替比夫定治疗慢性乙型肝炎的疗效。[方法]将164例慢性乙型肝炎患者分为治疗组85例,对照组79例,分别应用替比夫定和拉米夫定抗病毒治疗48周以观察其疗效。[结果]治疗组和对照组ALT复常率,HBeAg阳性分别为87.50%和71.15%;HBV DNA下降值HBeAg阳性为-5.3和-4.2log10copies/ml,阴性为-6.6和-5.5log10 copies/ml;HBeAg转阴率分别为28.57%和23.08%;HBeAg血清转换率为23.21%和15.38%;耐药率HBeAg阳性为3.57%和11.53%,阴性为3.45%和14.81%;差异有显著性(P<0.05)。[结论]替比夫定具有抗乙型肝炎病毒特异性,与拉米夫定比较,其抑制病毒能力强,病毒耐药发生率低,HBeAg血清转换率高,安全性好。
[Objective] To discuss the efficacy of Telbivudine treating chronic hepatitis B. [Method] Randomly divide 164 cases into treatment group 85 and control one 79, respectively taking Telbivudine and Ramivudine for anti virus for 48 w, then observe their efficacy. [Result] The ALT normalization and HbeAg positive rates were separately 87.50% and 71.15 % for both groups; HBV DNA reduction rates and HbeAg postive -5.3 and -4.2log10 copies/ml,negative -6.6 and -5.5 log10 eopies/ml;HbeAg negative rates respectively 28.57 % and 23.08% ; HbeAg serum conversion rates 23.21% and 15.38% ;resistance rates of HbeAg positive 3.57% and 11.53 %, negative 3.45% and 14.81 % ; the difference was very obvious （ P〈0.05 ）. [Conclusion] Telbivudine has specificity of anti virus hepatitis;compared with Ramivudine, it has strong virus inhibition, with low virus resistance rate and high HbeAg serum conversion rate, and good safety.
出处
《浙江中医药大学学报》
CAS
2009年第2期214-215,共2页
Journal of Zhejiang Chinese Medical University
